Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTH gel Clear all
Withdrawn Phase 4 Interventional

Acthar for Treatment of Post-transplant FSGS

NCT02399462
View directory record Official record
Conditions
FSGS, Renal Transplantation, Kidney Transplantation
Interventions
Acthar
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 4 Interventional

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

NCT02188017
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

ACTH Gel Therapy in Rheumatoid Arthritis

NCT02030028
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ACTHAR gel
Drug
Lead sponsor
Dana Ascherman
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 4 Interventional

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

NCT03082573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar gel
Drug
Lead sponsor
Iraj Sabahi Research Inc.
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pleasanton, California • Turlock, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed No phase listed Observational

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

NCT03644771
View directory record Official record
Conditions
Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function
Interventions
Acthar
Drug
Lead sponsor
Greater Boston Medical Associates
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177
View directory record Official record
Conditions
Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
Interventions
Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 4 Interventional Results available

Use of CXCL9 as a Biomarker of Acthar Efficacy

NCT02523092
View directory record Official record
Conditions
Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

NCT00947895
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Methylprednisolone, ACTH, IV placebo, IM placebo
Drug · Other
Lead sponsor
Neurologique Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ponte Vedra, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Not applicable Interventional

Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)

NCT01367964
View directory record Official record
Conditions
West Syndrome
Interventions
adrenocorticotropin hormone
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Months to 12 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Not applicable Interventional

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

NCT01900093
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Aaron Miller
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 4 Interventional Results available

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

NCT02769702
View directory record Official record
Conditions
Uveitis
Interventions
Acthar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 2Phase 3 Interventional

ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial

NCT02348905
View directory record Official record
Conditions
Sarcoidosis, Cutaneous Sarcoidosis
Interventions
ACTHAR Gel 40 units twice weekly, ACTHAR Gel 80 units twice weekly.
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

NCT01769937
View directory record Official record
Conditions
Lupus Erythematosus Systemic Exacerbation
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 2Phase 3 Interventional

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

NCT02155803
View directory record Official record
Conditions
Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Interventions
ACTHAR Gel (adrenocorticotropic hormone)
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed No phase listed Observational

(ACTH) for the Treatment of Sarcoid Uveitis

NCT03473964
View directory record Official record
Conditions
Sarcoid Uveitis
Interventions
H.P. Acthar gel
Drug
Lead sponsor
John Huang, MD
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
ACTH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

NCT03068754
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Acthar, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Effects of Acthar on Recovery From Cognitive Relapses in MS

NCT02290444
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis

NCT03465111
View directory record Official record
Conditions
Scleritis
Interventions
ACTH (adrenocorticotropic hormone) gel
Drug
Lead sponsor
Metropolitan Eye Research & Surgery Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Palo Alto, California • Palisades Park, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

NCT04169061
View directory record Official record
Conditions
Keratitis
Interventions
Acthar
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554
View directory record Official record
Conditions
Proteinuria, Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 4 Interventional

A Trial of Neuroprotection With ACTH in Acute Optic Neuritis

NCT01838174
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR Gel (ACTH), IV methylprednisolone (steroids)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 4 Interventional

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

NCT01939132
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Open label H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Oct 22, 2026, 5:10 AM EDT